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Nebulized &receptor agonists may cause neutrophil demargination and result in misleading total circulating 
leukocyte counts (WBCs) in patients with acute bronchospasm. Varying underlying adrenergic stimulation in these 
patients also makes interpretation of these data difficult. This study examined the direct effect of these agents on the 
measured WBCs of healthy adults without evidence of bronchospasm or illness. 
A prospective, blinded, randomized study of 30 healthy volunteers (aged 18-50 years) was performed in a 
controlled environment. Subjects were excluded if they were pregnant, had a known underlying medical disorder or 
have had a prior reaction to albuterol or similar medications. Participants in the study were given either a nebulized 
albuterol treatment or nebulized normal saline (control group). Leukocyte counts were then obtained before and 
after treatments. Paired data were analysed using a one-tailed t-test while considering an increase of 40% in WBCs 
to be significant, P=O.O5, and fi=O.lO. 
Mean leukocyte counts were 5.9 ( f 1.2) before treatment as compared to 6.0 ( & 1.3) after albuterol nebulization. 
Using the coefficient of variance of WBCs in normal humans as c. 50% (6000 & 3000 cells mn- ‘) we were unable to 
demonstrate a significant difference in variation in post-nebulized leukocyte counts between the control group and 
the nebulized albuterol group. 
While there is concern that the treatment of patients experiencing acute bronchospasm with p2 agonists may result 
in factitious elevations in peripheral leukocyte counts, we found no direct effect of these agents on measured counts 
in normal subjects. 
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Introduction 
Infectious processes can precipitate an acute exacerbation 
of bronchospasm in patients with chronic pulmonary dis- 
eases and asthma. Therefore, it is important to identify 
those patients with an underlying infection in order to speed 
recovery and prevent re-occurrence. Many physicians con- 
tinue to rely heavily on measured total circulating leukocyte 
counts (WBCs) as a basis for clinical decision-making (e.g. 
admission, further laboratory analysis, antibiotic therapy, 
etc.) despite evidence indicating a limited clinical usefulness 
of this test (14). Measurements of WBCs in patients with 
acute bronchospasm are often difficult to interpret due to 
the underlying adrenergic stimulation. The situation can 
be further complicated by the use of b-receptor agonist 
(e.g. epinephrine) which cause an increase in WBCs via a 
demarginating effect on neutrophils and lymphocytes 
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(5,6,7). Enberg et al. found that normal adult controls had 
a significantly greater increase in WBCs after treatment 
with epinephrine when compared to those patients with an 
acute asthma exacerbation treated with epinephrine (40% 
vs. 14%, respectively), mainly due to increased lymphocytes 
(8). 
The use of &receptor agonists has revolutionized the 
treatment of acute airway disease via inhalation of a 
nebulized solution. The most widely used &-receptor ago- 
nist, albuterol, is commonly used in the acute treatment of 
bronchospasm because it is efficacious and has minimal 
clinical systemic effects. There is concern that nebulized 
&-receptor agonists may also cause neutrophil demargina- 
tion and result in misleading WBC determinations. Prior 
studies have demonstrated varying effects of these agents on 
leukocyte counts in patients with bronchospasm. Shuh et al. 
found a 3-7% increase (above pretreatment baseline) in 
WBCs (due mainly to neutrophils) in asthmatics presenting 
with acute exacerbations and treated with nebulized 
albuterol (9). Most recently, Vetto and Moore found no 
difference in WBCs before and after albuterol nebulization 
treatment in adults presenting with bronchospasms 
secondary to asthma or COPD (10). They postulated that 
the lack of an increase in WBCs correlates with the minimal 
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TABLE 1. Pre- and postnebulization total peripheral leukocyte counts in cells mm- ’ (albuterol 
treated and controls) with differentials of Szsegmentary leukocytes, L=lymphocytes, and 
M=monocytes reported as percentages of total 
Pre-albuterol Post-albuterol Pre-control Post-control 
5.8 (SlS/32L/llM) 5.4 (48S/37L/l2M) 7.2 (58S/36L18M) 5.6 (61S/28L/12M) 
6.2 (60S/36L/8M) 5.9 (60S/30L/8M) 8.1 (59S/29L/9M) 8.0 (60S/30L/9M) 
5.8 (58S/32L/6M) 5.7 (53S/37L/6M) 5.5 (57S/35L/SM) 697 (56S/32L/l IM) 
5.6 (55S/29L/7M) 5.6 (54S/32L/7M) 5.4 (75S/20L/4M) 5.3 (49S/39L/6M) 
6.3 (34Sl55Ll7M) 6.8 (28S/62L/7M) 8.2 (56S/29L/8M) 8.0 (60S/27L/7M) 
7.5 (42S/46L/8M) 7.8 (38S/51L/8M) 7.0 (66S/28L/5M) 7.7 (64S/28L/8M) 
6.6 (48S/4OL/llM) 6.5 (48S/41L/lOM) 8.3 (58S/35L/6M) 7.4 (53S/36L/8M) 
6.7 (59S/31L/6M) 6.7 (57S134W5M) 6.0 (62S/30L/6M) 6.3 (61S/30L/6M) 
5.2 (63S/28L/9M) 5.3 (62S/28L/8M) 7.4 (55S/28L/8M) 7.7 (54Y26Ll9M) 
5.0 (49S/40L/8M) 6.4 (38S/54L/6M) 10 (63S/26L/6M) 10.2 (6lS/29L/7M) 
6.6 (52S/33L/7M) 6.0 (48S/39L/6M) 8.9 (70S/25L/3M) 8.5 (70S/26L/4M) 
8.0 (60S/30L/5M) 8.3 (34S/48L/9M) 8.2 (663/21L/8M) 8.1 (64S/23L/8M) 
5.3 (6lS/20L/12M) 5.6 (55S/27L/llM) 6.4 (62St27LJlOM) 6.3 (64S/25L/9M) 
5.5 (598/31L/8M) 5.9 (55S/36L/7M) 4.9 (52Y36LlllM) 5.2 (50S/35L/12M) 
2.7 (34S/45L/l7M) 2.5 (34S/50L/13M) 9.7 (6lS/25L/llM) 9.1 (56S/30L/l4M) 
side-effects of albuterol and, hence, emphasizes its lack of 
significant systemic absorption (8-10). In all of these 
studies, the baseline WBCs in these acutely ill patients were 
at or above the upper limits of normal. In addition, 
confounding variations in haemodynamic and adrenergic 
states in the pre- and post-treatment conditions of these 
patients make interpretation of these data difficult. The 
current study examined the direct effect of nebulized 
albuterol on the measured WBCs of healthy adults without 
bronchospasm and under controlled conditions. If 
albuterol does affect measured circulating leukocyte counts 
this would indicate that WBCs are of limited use in clinical 
decision-making in patients receiving these agents (l-3). 
Otherwise, a negative result would support the contention 
that systemic absorption of inhaled albuterol using normal 
pharmacological doses is minimal. This would confirm the 
apparent lack of significant systemic effects (heart rate and 
blood pressure changes) associated with albuterol use, 
unlike those seen with many other sympathomimetic agents 
(8-10). 
Methods 
A prospective, double-blind, randomized study of 30 
healthy recruited volunteers (18-50 years old) was per- 
formed in a controlled environment. Subjects were excluded 
if they were pregnant, had a known underlying cardiac, 
pulmonary, renal, allergic, immunological, neurological or 
haematological disorder, or have had a prior reaction to 
albuterol or similar medications. In 30 study participants 
who meet the above criteria, a complete baseline blood 
count (CBC) was collected by phlebotomy (5 ml antecub- 
itally) immediately prior to administration of a nebulized 
solution. The volunteers were then randomized into treat- 
ment and control groups of 15 patients each. The treatment 
group received nebulized albuterol solution (2.5 mg in 3 ml 
of normal saline). The control group received nebulized 
normal saline (3 ml) only. Twenty minutes after the com- 
pletion of the nebulized solution, a second CBC was 
collected (5 ml antecubitally). The CBCs were sent to the 
clinical laboratory for routine analysis (including differen- 
tials), and the results were compared descriptively and 
subjected to statistical analysis. Using the coefficient of 
variance of WBCs in normal humans as c. 50% 
(6000 5 3000 cells mm - *) paired data were analysed using 
a one-tailed t-test while considering an increase of 40% in 
WBCs to be significant, PxO.05, and p=O.lO. 
Results 
The results of the CBC analyses for all 30 subjects are listed 
in Table 1. In the 15 volunteers who received albuterol, the 
leukocyte counts averaged 5.9 ( & 1.2) cells mm - ’ before 
treatment as compared to 6.0 ( f 1.3) cells mm - ’ after the 
nebulized therapy. In the 15 volunteers who received saline 
only, the leukocyte counts averaged 7.4 ( * 1.5) cells mm - ’ 
before treatment as compared to 7.3 ( & 1.4) cells mm - ’ 
after the nebulization. Statistical analysis failed to demon- 
strate a significant difference in the variation between the 
control group and the nebulized albuterol group in 
postnebulized leukocyte counts or their differentials. 
Conclusion 
While there is concern that the treatment of patients 
experiencing acute bronchospasm with & agonists may 
result in factitious elevations in peripheral leukocyte 
counts, we found no direct effect of these agents on the 
measured WBCs or their differentials under controlled 
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conditions. As noted before this finding supports the con- 
tention that the systemic absorption of inhaled albuterol 
using normal pharmacological doses is minimal. However, 
adrenergic stimulation during acute bronchospasm may 
still result in artificially high leukocyte counts and should be 
considered in any clinical decision-making process. 
There are several minor limitations of the study worth 
noting. It is uncertain if the use of the 20-min waiting 
period after nebulization before drawing the blood samples 
is optimal for determining the effect. However, the time- 
frame of 20 min post-nebulization should ‘catch’ the 
demarginated neutrophils and lymphocytes, as this effect is 
almost immediate, and is probably maximal at about 
20 min (11-14). 
The artificial setting of the study prohibits examining the 
possible synergistic effects of the albuterol with the condi- 
tions of adrenergic stimulation and haemodynamic hyper- 
activity. While we do not know if such a synergism actually 
exists, previously published clinical studies suggest that this 
is not an important consideration (10). Furthermore, our 
study was designed to dissect out the selective action of 
albuterol on demargination of leukocytes independent of 
other controlling variables. 
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